KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease

Michelle O. Forgione(University of Adelaide), Deborah L. White(ANZCHOG), David T Yeung(South Australia Pathology), Laura N Eadie(South Australian Health and Medical Research Institute), Barbara J. McClure(South Australian Health and Medical Research Institute)

Cancer Letters

November 6, 2019

10.1016/j.canlet.2019.11.005

Cited by 49

Related Papers

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

|New England Journal of Medicine|2014|1.4k

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

|Blood|2013|705

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

|New England Journal of Medicine|2019|464

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

|Nature Medicine|2020|289

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

|Blood|2018|208